The Pharmaceutical Benefits Advisory Committee has recommended a change to the listing of a popular class of diabetes medicines and a 15 per cent price reduction.
PBAC says a price reduction of 'at least 15%' would be appropriate
December 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
New Zealand moves again to make it easier to access medicines
July 11, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 July
July 10, 2025 - - Podcast -
'The debate is frustrating but it is an opportunity to amplify acknowledged concerns'
July 10, 2025 - - Latest News -
Medibank to subsidise pharmacogenetic testing for members
July 10, 2025 - - Latest News -
Is this the missing link in pharma engagement strategies?
July 9, 2025 - - Latest News -
Stakeholders welcome medicinal cannabis crackdown
July 9, 2025 - - Latest News -
Might Australia be just a little hypocritical on pharmaceutical tariffs?
July 9, 2025 - - Latest News